Efficacy and safety of anlotinib plus EGFR tyrosine kinase inhibitors in slow- or locally progressing non-small cell lung cancer after adjuvant therapy

Jiayue Ye, Jiacong Liu, Yucheng Ma, Wang Lv, Wenzhen Xu, Masaya Aoki, Yuhong Yang, Pinghui Xia, Luming Wang, Linhai Zhu, Jian Hu